Intech Investment Management LLC Increases Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Intech Investment Management LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 195,587 shares of the biopharmaceutical company's stock after buying an additional 3,038 shares during the period. Intech Investment Management LLC's holdings in Gilead Sciences were worth $18,066,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Swedbank AB grew its holdings in shares of Gilead Sciences by 10.2% during the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock worth $171,672,000 after purchasing an additional 189,622 shares during the last quarter. Natixis Advisors LLC grew its holdings in shares of Gilead Sciences by 18.1% during the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company's stock worth $14,199,000 after purchasing an additional 25,912 shares during the last quarter. Claro Advisors LLC grew its holdings in shares of Gilead Sciences by 16.1% during the third quarter. Claro Advisors LLC now owns 8,555 shares of the biopharmaceutical company's stock worth $717,000 after purchasing an additional 1,187 shares during the last quarter. TrinityPoint Wealth LLC grew its holdings in shares of Gilead Sciences by 658.5% during the third quarter. TrinityPoint Wealth LLC now owns 43,606 shares of the biopharmaceutical company's stock worth $3,656,000 after purchasing an additional 37,857 shares during the last quarter. Finally, Aljian Capital Management LLC purchased a new position in shares of Gilead Sciences during the third quarter worth about $479,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the completion of the sale, the chief financial officer now directly owns 169,061 shares of the company's stock, valued at approximately $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders sold 302,785 shares of company stock valued at $30,503,250. Company insiders own 0.29% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on GILD shares. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their price target on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, Bank of America raised their price target on Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $104.52.

Gilead Sciences Price Performance

Shares of GILD stock traded up $1.21 during midday trading on Friday, reaching $107.08. 26,496,292 shares of the company traded hands, compared to its average volume of 6,797,069. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The firm has a market cap of $133.35 billion, a PE ratio of 289.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The firm's 50 day simple moving average is $103.68 and its two-hundred day simple moving average is $93.75.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be paid a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.95%. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.